Pfizer reports ‘positive’ results from TALAPRO-2 study of TALZENNA/XTANDI

Pfizer announced positive topline results from the final prespecified overall survival analysis of the TALAPRO-2 study of TALZENNA, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI, an androgen receptor pathway inhibitor, in patients with metastatic castration-resistant prostate cancer. Results showed a statistically significant and clinically meaningful improvement in the final OS in all-comers as well as in those patients with homologous recombination repair gene-mutated mCRPC, compared to XTANDI alone. “The TALAPRO-2 results showed that TALZENNA plus XTANDI is the first and only PARP inhibitor in combination with an ARPI to significantly improve survival in patients with metastatic castration-resistant prostate cancer, regardless of mutation status,” said Roger Dansey, M.D., Chief Development Officer, Oncology, Pfizer. “Pfizer is dedicated to advancing scientific breakthroughs in genitourinary cancers, and these exciting TALAPRO-2 results further highlight our long-standing commitment to improving survival for men with prostate cancer.”